

# Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimens

Published: 08-05-2009

Last updated: 06-05-2024

The primary purpose of the study is to determine the efficacy of AZD2281 compared to placebo in serous ovariancancer platinum sensitive patients and in a defined HRD subset.

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	Reproductive neoplasms female malignant and unspecified
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON43643

### Source

ToetsingOnline

### Brief title

platinum sensitive serous ovarian cancer

### Condition

- Reproductive neoplasms female malignant and unspecified

### Synonym

cancer of the ovaries

### Research involving

Human

## Sponsors and support

**Primary sponsor:** Astra Zeneca

**Source(s) of monetary or material Support:** Astra Zeneca

## Intervention

**Keyword:** ovarian cancer, Phase II, platinum sensitive

## Outcome measures

### Primary outcome

PFS as evaluated by RECIST

### Secondary outcome

Efficacy: OS, best overall response, duration of response, CA-125 response

(GCIG criteria), time to progression by CA-125 (GCIG criteria) or RECIST,

Quality of Life (QoL) and disease related symptoms.

Measurement of candidate biomarkers (including but not limited to ATM,

MRE-11, MDC1, BRCA1/2) to identify the Homologous Recombination

Deficient subset of tumours for correlation with benefit/risk of treatment with

AZD2281.

Safety: AEs, physical examination, vital signs including BP, pulse, ECG and

laboratory findings including clinical chemistry, haematology and urinalysis.

## Study description

### Background summary

AZD2281 monotherapy has demonstrated significant anti-tumour activity, (while

being well tolerated) for ovarian cancer patients (previously treated with platinum agents) harbouring mutations in BRCA1 or BRCA2 (AstraZeneca, unpublished data). Many studies have indicated BRCA1/2 mutations and other BRCA1/2 defects are predominantly found within the serous subset of ovarian cancer patients. It is therefore hypothesised that AZD2281 will have significant anticancer activity in a large proportion of serous ovarian cancer patients. Please see page 25 of the study protocol

## **Study objective**

The primary purpose of the study is to determine the efficacy of AZD2281 compared to placebo in serous ovarian cancer platinum sensitive patients and in a defined HRD subset.

## **Study design**

The study is a randomised, double blind, multi-centre study in platinum sensitive serous ovarian cancer patients who have received 2 or more previous platinum containing regimens. Platinum sensitivity is defined as disease progression greater than 6 months after completion of their penultimate platinum regimen (from last dose) prior to enrolling on this study. In the last platinum regimen prior to enrolling on this study, patients must have demonstrated an objective stable maintained response (complete, or partial response by GCIG and/or RECIST) and this response needs to be maintained to allow entry to the study. The two platinum regimens do not necessarily have to be sequential.

Patients will be randomised within 8 weeks after their last dose of the platinum containing regimen. Randomisation will be stratified by time to disease progression (>6-12 months and >12 months, in the penultimate platinum therapy prior to enrolment), objective response (CR or PR, in the last platinum therapy prior to enrolment) and whether a patient is of Jewish descent (yes or no).

## **Intervention**

Patients will be randomised in a 1:1 ratio (AZD2281:matching placebo) to one of 2 arms:

1. AZD2281 400mg bid
2. AZD2281 matching placebo bid

### **Study burden and risks**

\* Burden: Patients will be asked to come to the site 14 times during the first 6 months.

Screening 2 - 2.5h = 30 minutes physical exam + anamnesis + Lab 30 min + 30 min CT + 30 min ECG + 30 min QoL

2nd Screening (if indicated) = Lab 15 min

First 8 weeks (2 cycles)= once a week - 30 minutes per visit

Every month / every two months - 1h visit

Expected duration study from previous clinical experience: 6-12 months, until disease progression

Total patient visit time based on expected study duration: 10-16h

\* Risks are the possible side-effects of the study medication and risks associated with the study procedures like blood draws, CT- or MRI-scans and ECG. The side effects most commonly associated with AZD2281 are: anaemia, neutropenia and thrombocytopenia, nausea, vomiting and fatigue.

## **Contacts**

### **Public**

Astra Zeneca

Alderley Park, Macclesfield -  
Parksland, Cheshire SE1 K/1  
GB

### **Scientific**

Astra Zeneca

Alderley Park, Macclesfield -  
Parksland, Cheshire SE1 K/1  
GB

## **Trial sites**

## Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

1. Provision of voluntary obtained informed consent prior to any study specific procedures.
2. Female patients, > 18 years of age, with histologically diagnosed serous ovarian cancer or recurrent serous ovarian cancer with a histology type of serous, or a serous component and who have completed at least 2 previous courses of platinum containing therapy (e.g. carboplatin or cisplatin)
3. Formalin fixed, paraffin embedded tumour sample from the cancer must be available for central testing.

### Exclusion criteria

1. Patients with low grade ovarian carcinoma.
2. Patients who have had drainage of their ascites during the final 2 cycles of their last chemotherapy regimen prior to enrolment on the study.
3. Previous treatment with PARP inhibitors including AZD2281.

## Study design

### Design

Study phase:	2
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

Primary purpose: Treatment

## Recruitment

NL  
Recruitment status: Recruitment stopped  
Start date (anticipated): 15-10-2009  
Enrollment: 8  
Type: Actual

## Medical products/devices used

Product type: Medicine  
Brand name: nog niet bekend  
Generic name: olaparib

## Ethics review

Approved WMO  
Date: 08-05-2009  
Application type: First submission  
Review commission: PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)

Approved WMO  
Date: 23-07-2009  
Application type: First submission  
Review commission: PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)

Approved WMO  
Date: 14-10-2009  
Application type: Amendment  
Review commission: PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)

Approved WMO  
Date: 25-03-2010  
Application type: Amendment  
Review commission: PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)

Approved WMO	
Date:	19-07-2010
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO	
Date:	14-03-2011
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO	
Date:	26-09-2011
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO	
Date:	16-01-2012
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO	
Date:	14-06-2012
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO	
Date:	27-12-2012
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO	
Date:	23-08-2013
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO	
Date:	09-01-2014
Application type:	Amendment

Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	21-01-2014
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	08-08-2014
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	23-03-2016
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)
Approved WMO Date:	15-04-2016
Application type:	Amendment
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers



**Register**

EudraCT

ClinicalTrials.gov

CCMO

**ID**

EUCTR2008-003439-18-NL

NCT00753545

NL27719.031.09